Cosmos Health Secures Additional 180-Day Nasdaq Extension to Regain Bid Price Compliance
Rhea-AI Summary
Cosmos Health (NASDAQ:COSM) received a further 180-day Nasdaq extension, until December 7, 2026, to regain compliance with the $1.00 minimum bid price requirement.
The company meets all other Nasdaq Capital Market listing criteria and aims to restore compliance by executing its business strategy, treating any potential reverse stock split as a last resort.
Positive
- Nasdaq grants additional 180-day extension through December 7, 2026
- Company meets all other Nasdaq Capital Market listing requirements
- Compliance can be regained with 10 consecutive days above $1.00 bid
- Management emphasizes business execution to enhance shareholder value
Negative
- Shares remain below Nasdaq $1.00 minimum bid price requirement
- Ongoing risk of delisting if compliance not regained by December 7, 2026
- Reverse stock split remains a possible last-resort measure
News Market Reaction – COSM
In the Jun 11 session, COSM declined 9.69%, reflecting a notable negative market reaction. Argus tracked a peak move of +7.0% during that session. Argus tracked a trough of -8.4% from its starting point during tracking. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Crypto Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 10 | Manufacturing agreement | Positive | +2.1% | Three-year deal to produce 3.9M VASCLOR GEST progesterone pessary units. |
| Jun 09 | New production line | Positive | -7.8% | Launch of capsule line and five-year CERTORUN contract manufacturing agreement. |
| Jun 05 | Product launch | Positive | -7.4% | U.S. launch of Oliv18 nutraceutical targeting cardiovascular and antioxidant markets. |
| Jun 04 | EU distribution expansion | Positive | +9.8% | Pan‑EU Skroutz distribution for Sky Premium Life across all 27 EU states. |
| Jun 04 | Asset monetization plan | Positive | +9.8% | Identification of about $20M in non‑core assets for potential monetization. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent same-tag news is mostly operationally positive, with three instances where the stock moved up on good news and two cases of selloffs despite favorable updates.
Over early June 2026, Cosmos Health issued a stream of growth-focused announcements: new contract manufacturing deals, a capsule production line, a U.S. nutraceutical launch, pan‑EU distribution for Sky Premium Life, and identification of about $20 million in non‑core assets for potential monetization. These crypto‑tagged updates emphasize expansion, manufacturing scale, and balance sheet optimization, forming the backdrop for today’s Nasdaq bid‑price compliance extension.
Key Terms
minimum bid price regulatory
reverse stock split financial
nasdaq capital market regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Extension granted through December 7, 2026
- Reflects the Company's compliance with all other applicable Nasdaq listing requirements.
- Cosmos Health does not intend to effect a reverse stock split unless necessary to maintain its Nasdaq listing.
CHICAGO, June 11, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has been granted an additional 180-day period to regain compliance with the Nasdaq minimum bid price requirement.
On June 10, 2026, the Company received written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") granting it an additional period, through December 7, 2026, to regain compliance with the
Nasdaq determined that the Company is eligible for the additional period based on its compliance with the market value of publicly held shares requirement and all other applicable requirements for initial listing on the Nasdaq Capital Market, with the exception of the bid price requirement.
To regain compliance, the closing bid price of the Company's common stock must be at least
The Company's primary focus is to regain compliance through the continued execution of its business strategy and initiatives to enhance shareholder value. While it has the ability to effect a reverse stock split if necessary, Cosmos Health regards this as a measure of last resort and does not intend to implement one unless required to maintain its Nasdaq listing.
Greg Siokas, CEO of Cosmos Health, stated: "Our strong preference is to regain compliance without a reverse stock split, and our plan is built around executing on our business — growing revenues, advancing our pipeline, and creating real value for shareholders. We regard a reverse split strictly as a measure of last resort, to be used only if it becomes necessary to preserve our Nasdaq listing for the benefit of our shareholders. We are actively pursuing a range of initiatives to unlock and enhance shareholder value, and we look forward to updating our shareholders as we make progress.”
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company’s business, operations, and the economy in general; the Company’s ability to successfully develop and commercialize its proprietary products and technologies; changes in interest rates; changes in foreign currency exchange rates, commodity or other price inflation and deflation; our ability to issue debt on terms and at rates acceptable to us; the impact and expected outcome of investigations, inquiries, claims, and litigation; the challenges of operating in international markets; the adequacy of insurance coverage; the effect of accounting charges and of adopting certain accounting standards; the impact of legal and regulatory changes, including changes to tax laws and regulations; guidance for fiscal 2026 and beyond and financial outlook. Forward-looking statements are based on currently available information and our current assumptions, expectations and projections about future events. You should not rely on our forward-looking statements. These statements are not guarantees of future performance and are subject to future events, risks and uncertainties – many of which are beyond our control, dependent on the actions of third parties, or currently unknown to us – as well as potentially inaccurate assumptions that could cause actual results to differ materially from our historical experience and our expectations and projections. These risks and uncertainties include, but are not limited to, those described from time to time in our periodic reports filed with the SEC and available at the SEC’s website (www.sec.gov). There also may be other factors that we cannot anticipate or that are not described herein, generally because we do not currently perceive them to be material. Such factors could cause results to differ materially from our expectations. Forward-looking statements speak only as of the date they are made, and we do not undertake to update these statements other than as required by law. You are advised, however, to review any further disclosures we make on related subjects in our filings with the Securities and Exchange Commission and in our other public statements.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
